TR200102963T2 - Yeni tedavi metodu - Google Patents

Yeni tedavi metodu

Info

Publication number
TR200102963T2
TR200102963T2 TR2001/02963T TR200102963T TR200102963T2 TR 200102963 T2 TR200102963 T2 TR 200102963T2 TR 2001/02963 T TR2001/02963 T TR 2001/02963T TR 200102963 T TR200102963 T TR 200102963T TR 200102963 T2 TR200102963 T2 TR 200102963T2
Authority
TR
Turkey
Prior art keywords
treatment method
new treatment
amoxycillin
administered
treated
Prior art date
Application number
TR2001/02963T
Other languages
English (en)
Turkish (tr)
Inventor
Storm Kevin
Conley Creighton
Roush John
Original Assignee
Beecham Pharmaceuticals (Pte) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27383840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200102963(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Pharmaceuticals (Pte) Limited filed Critical Beecham Pharmaceuticals (Pte) Limited
Publication of TR200102963T2 publication Critical patent/TR200102963T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Peptides Or Proteins (AREA)
TR2001/02963T 1999-04-13 2000-04-11 Yeni tedavi metodu TR200102963T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12907499P 1999-04-13 1999-04-13
US15072799P 1999-08-25 1999-08-25
US15981399P 1999-10-15 1999-10-15

Publications (1)

Publication Number Publication Date
TR200102963T2 true TR200102963T2 (tr) 2002-02-21

Family

ID=27383840

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02963T TR200102963T2 (tr) 1999-04-13 2000-04-11 Yeni tedavi metodu

Country Status (44)

Country Link
EP (4) EP1044680B1 (enExample)
JP (2) JP4880125B2 (enExample)
KR (1) KR100634937B1 (enExample)
CN (1) CN100382782C (enExample)
AP (1) AP1806A (enExample)
AR (1) AR031068A1 (enExample)
AT (2) ATE242629T1 (enExample)
AU (1) AU767177B2 (enExample)
BE (2) BE1012733A6 (enExample)
BG (1) BG65006B1 (enExample)
BR (1) BRPI0009719B8 (enExample)
CA (1) CA2366304C (enExample)
CO (1) CO5170471A1 (enExample)
CZ (1) CZ298801B6 (enExample)
DE (3) DE20006626U1 (enExample)
DK (3) DK200000602A (enExample)
DZ (1) DZ3150A1 (enExample)
EA (1) EA004310B1 (enExample)
ES (2) ES2190692B1 (enExample)
FI (2) FI4823U1 (enExample)
FR (1) FR2792198A1 (enExample)
GB (1) GB2351661B (enExample)
GR (1) GR1003560B (enExample)
HU (1) HU229097B1 (enExample)
IE (1) IE20000271A1 (enExample)
IL (2) IL145580A0 (enExample)
IT (1) ITMI20000788A1 (enExample)
MA (1) MA25352A1 (enExample)
MX (1) MXPA01010377A (enExample)
MY (1) MY119953A (enExample)
NL (2) NL1014915C2 (enExample)
NO (1) NO329694B1 (enExample)
NZ (1) NZ514575A (enExample)
OA (1) OA11926A (enExample)
PE (1) PE20010053A1 (enExample)
PL (1) PL197448B1 (enExample)
PT (2) PT102450B (enExample)
RO (1) RO120817B1 (enExample)
SE (1) SE0001330L (enExample)
SI (2) SI20304A (enExample)
SK (1) SK285140B6 (enExample)
TR (1) TR200102963T2 (enExample)
TW (1) TWI235067B (enExample)
WO (1) WO2000061116A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
AU711441B2 (en) * 1995-09-07 1999-10-14 Smithkline Beecham Plc Pharmaceutical formulation
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
WO2003004031A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
EP1499303A4 (en) * 2002-04-10 2007-07-25 Fred H Miller MULTIPHASE MULTI-COMPONENT CAPSULE SYSTEM
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1541129A1 (en) * 2003-12-12 2005-06-15 Cimex AG Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2005099672A1 (en) * 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
EP1880716A1 (en) * 2006-07-19 2008-01-23 Sandoz AG Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
CA2652981C (en) * 2006-10-10 2012-05-01 Penwest Pharmaceuticals Co. Robust sustained release formulations
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
AU2016246583B2 (en) 2015-04-07 2020-06-25 Church & Dwight Co., Inc. Multicomponent gummy compositions with soft core
CN109394718B (zh) * 2018-11-15 2021-04-27 石药集团中诺药业（石家庄）有限公司 一种阿莫西林分散片及其制备方法
CN110051637A (zh) * 2019-05-21 2019-07-26 葵花药业集团北京药物研究院有限公司 阿莫西林克拉维酸钾制剂及其制备方法
CN117503721A (zh) * 2022-04-29 2024-02-06 越洋医药开发(广州)有限公司 一种吡非尼酮持续性释放口服固体制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008905B1 (en) * 1978-09-06 1983-02-16 Beecham Group Plc Pharmaceutical compositions containing two beta-lactam derivatives
IL58461A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
EP1034784A3 (en) * 1993-01-22 2001-06-27 Smithkline Beecham Plc Pharmaceutical formulations containing clavulanic acid and an antibacterial agent
GB9311030D0 (en) * 1993-05-28 1993-07-14 Smithkline Beecham Corp Pharmaceutical formulations
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
ITMI941169A1 (it) * 1994-06-06 1995-12-06 Smithkline Beecham Farma Formulazioni farmaceutiche
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
AU711441B2 (en) * 1995-09-07 1999-10-14 Smithkline Beecham Plc Pharmaceutical formulation
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
PL334976A1 (en) * 1997-02-14 2000-03-27 Smithkline Beecham Lab Pharmaceutic preparations containing amoxycyclin and clavulate
AU2104197A (en) * 1997-03-11 1998-09-29 Almag Al Process and apparatus for coating metals
SE9700885D0 (sv) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
CA2282531A1 (en) * 1997-03-25 1998-10-01 Takeda Chemical Industries, Ltd. Gastrointestinal mucosa-adherent pharmaceutical composition
JP3746901B2 (ja) * 1997-10-15 2006-02-22 ユニ・チャーム株式会社 開閉自在容器
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
GB9818927D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Pharmaceutical formulation
US6225304B1 (en) * 1999-02-17 2001-05-01 Pharmaceutical Solutions, Inc. Soluble forms of amoxicillin and treatment of animals

Also Published As

Publication number Publication date
ATE242629T1 (de) 2003-06-15
GB2351661B (en) 2001-10-10
DK200000133U3 (da) 2000-07-28
CZ298801B6 (cs) 2008-02-06
FI20000863A0 (fi) 2000-04-11
BE1013309A5 (fr) 2001-11-06
DE60003255T2 (de) 2004-05-06
EP1044680B1 (en) 2003-06-11
ITMI20000788A0 (it) 2000-04-11
OA11926A (en) 2006-04-12
PT102450A (pt) 2001-02-01
SI20304A (sl) 2001-02-28
PT102450B (pt) 2003-09-30
KR20020015312A (ko) 2002-02-27
WO2000061116A3 (en) 2001-02-01
EA200101075A1 (ru) 2002-04-25
HU229097B1 (en) 2013-07-29
ITMI20000788A1 (it) 2001-10-11
JP2011256180A (ja) 2011-12-22
AU767177B2 (en) 2003-11-06
BR0009719A (pt) 2002-01-08
EP1044680A1 (en) 2000-10-18
PL339591A1 (en) 2000-10-23
KR100634937B1 (ko) 2006-10-17
BRPI0009719B8 (pt) 2021-05-25
NO329694B1 (no) 2010-12-06
EA004310B1 (ru) 2004-02-26
NZ514575A (en) 2004-05-28
AP1806A (en) 2007-12-14
FIU20000164U0 (fi) 2000-04-11
SK5342000A3 (en) 2000-11-07
JP2002541187A (ja) 2002-12-03
DK200000602A (da) 2000-10-14
BR0009719B1 (pt) 2014-09-30
CZ20001311A3 (cs) 2000-11-15
FI20000863L (fi) 2000-10-13
GR1003560B (el) 2001-03-16
BG65006B1 (bg) 2006-12-29
EP1270005A2 (en) 2003-01-02
IL145580A (en) 2007-05-15
BE1012733A6 (fr) 2001-02-06
IE20000271A1 (en) 2001-04-04
GB2351661A (en) 2001-01-10
CA2366304A1 (en) 2000-10-19
MY119953A (en) 2005-08-30
TWI235067B (en) 2005-07-01
EP1269997A1 (en) 2003-01-02
MA25352A1 (fr) 2001-12-31
CN100382782C (zh) 2008-04-23
CA2366304C (en) 2004-06-29
DE20006626U1 (de) 2000-10-19
PE20010053A1 (es) 2001-03-10
AT4327U1 (de) 2001-06-25
NL1014915C2 (nl) 2001-02-12
AU5702000A (en) 2000-11-14
IL145580A0 (en) 2002-11-10
CN1382040A (zh) 2002-11-27
HUP0001471A2 (en) 2001-03-28
DK1044680T3 (da) 2003-09-29
ES2202004T3 (es) 2004-04-01
JP4880125B2 (ja) 2012-02-22
SI1044680T1 (en) 2003-12-31
PT1044680E (pt) 2003-10-31
AR031068A1 (es) 2003-09-10
WO2000061116A2 (en) 2000-10-19
HU0001471D0 (en) 2000-06-28
ES2190692A1 (es) 2003-08-01
NO20001870D0 (no) 2000-04-11
CO5170471A1 (es) 2002-06-27
NL1014915A1 (nl) 2000-10-16
SE0001330D0 (sv) 2000-04-11
HUP0001471A3 (en) 2001-10-29
HK1032741A1 (en) 2001-08-03
FI4823U1 (fi) 2001-02-16
ES2190692B1 (es) 2004-11-16
FR2792198A1 (fr) 2000-10-20
SE0001330L (sv) 2000-10-14
MXPA01010377A (es) 2002-10-23
DE60003255D1 (de) 2003-07-17
GB0008923D0 (en) 2000-05-31
NO20001870L (no) 2000-10-16
PL197448B1 (pl) 2008-03-31
SK285140B6 (sk) 2006-07-07
BG104329A (en) 2001-11-30
DE10017883A1 (de) 2000-10-26
FI20000863A7 (fi) 2000-10-13
NL1014914C1 (nl) 2000-10-16
EP1269996A1 (en) 2003-01-02
EP1270005A3 (en) 2006-05-17
AP2001002284A0 (en) 2001-12-31
DZ3150A1 (fr) 2000-10-19
RO120817B1 (ro) 2006-08-30

Similar Documents

Publication Publication Date Title
TR200102963T2 (tr) Yeni tedavi metodu
TR200102962T2 (tr) Yeni tedavi metodu.
CY1109437T1 (el) ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ
DE69735367D1 (de) THERAPEUTISCHE MULTISPEZIFISCHE VERBINDUNGEN, DIE ANTIKÖRPER GEGEN DEN FCalpha-REZEPTOR ENTHALTEN
DE69303494D1 (de) Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
CO4560547A1 (es) Una forma de dosis de azitromicina y un metodo de trata- miento de una infeccion microbiana que involucra la adminis- tracion de azitromicina
TR199701490A2 (xx) 3-Hidroksipiridin-2-karbonasitamidester ve bunlar�n imalat�.
ATE275143T1 (de) Verbindungen
NO20070763L (no) Kombinasjonsterapi med radiomerket anti-CD20-antistoff i behandlingen av B-cellelymfom
PT859613E (pt) Utilizacao de flupirtina para a profilaxia e o tratamento de doencas associadas a uma alteracao do sistema celular hematopoietico
MX9201288A (es) Metodo de tratamiento.
UY26104A1 (es) Nuevo metodo de tratamiento.
ECSP003432A (es) Nuevo metodo de tratamiento
PT852497E (pt) Utilizacao de derivados de prostano e a sua combinacao com antibioticos no tratamento de infeccoes bacterianas
MY136408A (en) Active substance combinations and therapies for treating abuse of alcohol
SE9602145D0 (sv) New improved formulation for treatment of thromboembolism
UA40992A (uk) Спосіб лікування хворих на позагоспітальну пневмонію з тяжким перебігом
ES2139382T3 (es) Sistema terapeutico percutaneo para compuestos de silatran.
ES2062752T3 (es) Preparado de una sal de oxipurinol en forma oral para el tratamiento de hiperuricemia.
Zakir et al. Radioiodine treatment for hyperthyroidism–do royal college guidelines suggest too high a radioiodine dose?
ECSP961736A (es) Metodo de tratamiento
UA38148A (uk) Спосіб комплексного лікування коловидного облисіння
MX9603999A (es) Tratamiento de nefropatia diabetica con valsartan.
UA46682A (uk) Спосіб зняття потягу до алкоголю, у тому числі без бажання та згоди пацієнта